Folate Receptor alpha (FRα) in Ovarian Cancer: Utilizing this biomarker to support clinical decisions
In this session, Dr. Kevin Golden will address the new and upcoming biomarker, Folate Receptor alpha (FRα) and its clinical utility in ovarian cancer. Dr. Golden will discuss the results from the recent SORAYA study as well as some example cases and visuals of FRα to emphasize the importance of incorporating FRα into Ovarian cancer testing protocols.
Sign up today.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.
Agenda:
- Diaceutics - Welcome & introduction to Diaceutics
- Dr. Kevin Golden - Folate Receptor alpha (FRα) in Ovarian Cancer: Utilizing this biomarker to support clinical decisions
- All participants - Q&A
Speaker name: Dr Kevin Golden
Kevin Golden, MD/PhD, is currently the laboratory medical director for Mountainview Hospital in Las Vegas, NV, and an active participant in several research projects for Sonic Healthcare. Dr. Golden earned his PhD in neuroscience and medical degrees from the University in Miami Miller School of Medicine. His post-graduate training includes a residency in anatomic and clinical pathology and fellowships in surgical and gastrointestinal pathology at Brigham and Women's Hospital in Boston, MA.
Dr.Golden’s organizational interests are in development of new assays for prediction of behavior of malignant neoplasms and raising awareness for these new assays with relation to disease-specific diagnosis and prognosis.